Additive prognostic value of carbohydrate antigen‐125 over frailty in patients undergoing transcatheter aortic valve replacement

Background To evaluate the additive prognostic value of myocardial, inflammatory, and renal biomarkers according to frailty status in patients undergoing transcatheter aortic valve replacement (TAVR) for aortic stenosis (AS). Methods A total of 111 subjects who underwent TAVR at Hospital Italiano de...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Catheterization and cardiovascular interventions 2021-02, Vol.97 (2), p.E263-E273
Hauptverfasser: Romeo, Francisco José, Seropian, Ignacio Miguel, Chiabrando, Juan Guido, Raleigh, Juan Valle, Smietniansky, Maximiliano, Cal, Mariela, Falconi, Mariano, Kotowicz, Vadim, Agatiello, Carla Romina, Berrocal, Daniel Horacio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background To evaluate the additive prognostic value of myocardial, inflammatory, and renal biomarkers according to frailty status in patients undergoing transcatheter aortic valve replacement (TAVR) for aortic stenosis (AS). Methods A total of 111 subjects who underwent TAVR at Hospital Italiano de Buenos Aires, Argentina between January 2016 and December 2018 were retrospectively reviewed. Plasma levels of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), high sensitivity troponin T (hs‐cTnT), C‐reactive protein (CRP), cystatin‐c (Cys‐C) and carbohydrate antigen‐125 (CA‐125) were assessed prior to TAVR. Frailty status was assessed according to the fried physical frailty phenotype (FPFP). The primary endpoint was defined as all‐cause death and/or readmission for worsening congestive heart failure (CHF) within the first year after TAVR. Results Of the 111 patients included, 48/111 (43%) were considered to be “frail” according to the FPFP. Among biomarkers, we found CA‐125 to be strongly associated with the primary endpoint (p = .006). CA‐125 ≥ 18.2 U/ml was present in 41% and was associated with a higher rate of the primary endpoint (31% vs. 9%; p = .003). After multivariable adjustment, CA‐125 ≥ 18.2 U/ml (hazard ratio [HR] 3.17; p = .024) was the only independent predictor of the primary endpoint. Finally, the inclusion of CA‐125 to frailty significantly improved C‐index (0.68–0.74; p 
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.29067